Provided by Tiger Fintech (Singapore) Pte. Ltd.

Context Therapeutics Inc.

0.7060
+0.05248.02%
Post-market: 0.70600.00000.00%17:46 EDT
Volume:129.91K
Turnover:88.51K
Market Cap:63.33M
PE:-0.98
High:0.7186
Open:0.6700
Low:0.6400
Close:0.6536
Loading ...

Company Profile

Company Name:
Context Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
5
Office Location:
2001 Market Street,Suite 3915,Unit #15,Philadelphia,Pennsylvania,United States
Zip Code:
19103
Fax:
- -
Introduction:
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Directors

Name
Position
Martin Lehr
Chief Executive Officer and Director
Richard Berman
Chairman and Director
Jennifer Evans Stacey
Director
Linda West
Director
Philip Kantoff
Director

Shareholders

Name
Position
Martin Lehr
Chief Executive Officer and Director
Alex Levit
Chief Legal Officer and Corporate Secretary
Bill Rencher
Head of CMC and Regulatory
Evan G. Dick
SVP of Research and Development
Tarek Sahmoud
Chief Medical Officer